Market Place
Sourcing Support
Celcuity Inc. Reports Q3 Financial Results & Corporate Update
14 Nov 2024 //
GLOBENEWSWIRE
Celcuity To Present at Upcoming Stifel & Jefferies Investor Conf
12 Nov 2024 //
GLOBENEWSWIRE
Celcuity to Release Q3 2024 Results & Host Webcast
07 Nov 2024 //
GLOBENEWSWIRE
Celcuity Reports Q2 2024 Financial Results And Corporate Update
14 Aug 2024 //
GLOBENEWSWIRE
Celcuity To Report Q2 2024 Results And Host Conference Call
07 Aug 2024 //
GLOBENEWSWIRE
Celcuity To Participate in Jefferies Global Healthcare Conference
03 Jun 2024 //
GLOBENEWSWIRE
Celcuity Announces Pricing of Underwritten Common Stock Offering
30 May 2024 //
GLOBENEWSWIRE
Celcuity Plans Phase 3 Gedatolisib Trial Secures 62M Debt Financing
30 May 2024 //
GLOBENEWSWIRE
Celcuity Reports Q1 Financial Results, Corporate Update
15 May 2024 //
GLOBENEWSWIRE
Celcuity Q1 2024 Results Release, Webcast/Call
08 May 2024 //
GLOBENEWSWIRE
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
04 Apr 2024 //
GLOBENEWSWIRE
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
27 Mar 2024 //
GLOBENEWSWIRE
Celcuity Schedules Release of Fourth Quarter & Full Year 2023 FYR
20 Mar 2024 //
GLOBENEWSWIRE
Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024
06 Mar 2024 //
GLOBENEWSWIRE
Celcuity to Participate in Cowen™s 44th Annual Health Care Conference
28 Feb 2024 //
GLOBENEWSWIRE
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 of Gedatolisib
22 Feb 2024 //
GLOBENEWSWIRE
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
20 Feb 2024 //
GLOBENEWSWIRE
Celcuity Presents Data on Therapeutic Effects of Gedatolisib in Breast Cancer
06 Dec 2023 //
GLOBENEWSWIRE
Celcuity to Present Preclinical Data for Gedatolisib
01 Dec 2023 //
GLOBENEWSWIRE
Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference
22 Nov 2023 //
GLOBENEWSWIRE
Celcuity Inc. Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results
06 Nov 2023 //
GLOBENEWSWIRE
Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences
01 Nov 2023 //
GLOBENEWSWIRE
Celcuity to Host Virtual Science Day for Investors
07 Sep 2023 //
GLOBENEWSWIRE
Celcuity Announces Plan to Conduct Phase 1b/2 Trial in mCRPC
22 Aug 2023 //
GLOBENEWSWIRE
Celcuity Enters into Collaboration with Bayer to Provide Nubeqa
22 Aug 2023 //
GLOBENEWSWIRE
Celcuity Inc. Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023
31 Jul 2023 //
GLOBENEWSWIRE
Celcuity Closes $100 Million Private Placement
12 Dec 2022 //
ACCESSWIRE
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib
09 Dec 2022 //
ACCESSWIRE
Celcuity Announces First Patient Dosed in PIII VIKTORIA-1 Trial of Gedatolisib
07 Dec 2022 //
ACCESSWIRE
Celcuity to Present Additional Data for Gedatolisib at Breast Cancer Symposium
22 Nov 2022 //
ACCESSWIRE
Celcuity Inc. Reports 3Q2022 Financial Results and Provides Corporate Update
10 Nov 2022 //
ACCESSWIRE
Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results
03 Nov 2022 //
ACCESSWIRE
Celcuity Inc. Reports Q2 2022 Rusult and Provides Corporate Update
11 Aug 2022 //
ACCESSWIRE
Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference
04 Aug 2022 //
ACCESSWIRE
Celcuity Schedules Release of Second Quarter 2022 Financial Results
04 Aug 2022 //
ACCESSWIRE
Celcuity Announces FDA BTD for Gedatolisib in Metastatic Breast Cancer
18 Jul 2022 //
ACCESSWIRE
Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates
16 May 2022 //
BIOSPACE
Celcuity to Participate in Upcoming Needham and Canaccord Conferences
05 Apr 2022 //
ACCESSWIRE
